



# Kongeriget Danmark

Patent application No.: PA 2003 00549

Date of filing: 09 April 2003

Applicant: NatImmune A/S  
(Name and address) Fruebjergvej 3  
DK-2100 Copenhagen Ø  
Denmark

Title: Mannan-binding lectin (MBL) treatment of SARS in individuals.


IPC: -

This is to certify that the attached documents are exact copies of the above mentioned patent application as originally filed.



**Patent- og Varemærkestyrelsen**  
Økonomi- og Erhvervsministeriet

27 April 2004

  
Pia Petersen

P 774 DK00

Patent- og  
Varemærkestyrelsen

09 APR. 2003

Modtaget

1

**Mannan-binding lectin (MBL) treatment of SARS in individuals**

5 The present invention pertains to the use of subunits and oligomers of mannan-binding lectin (MBL) in prophylactic and/or curative treatment of Severe Acute Respiratory Syndrome (SARS) in an individual.

10 SARS infection presents the symptoms of high fever, dry cough, myalgia (muscle soreness) and sore throat. Most individuals suffering from SARS develop breathing difficulties eventually requiring ventilator support, and severe thrombocytopenia. 5-10 percent of individuals suffering from SARS will eventually die due to the disease.

15 The cause of SARS is not yet known. It has been speculated that SARS may be caused by a virus and among these, coronaviruses and paramyxoviruses have been mentioned.

Symptoms of SARS seem to start 2-14 days after exposure.

**Summary of the invention**

20 By the present invention MBL treatment and/or prophylaxis of Severe Acute Respiratory Syndrome is suggested.

25 Mannan-binding lectin (MBL), synonymous to mannanose-binding lectin, mannan-binding protein or mannanose-binding protein (MBP), belongs to a subgroup of C-type lectins, termed collectins, since these soluble proteins are composed of subunits presenting three CRDs attached to a collagenous stalk<sup>2</sup>. MBL interact with carbohydrates presented by a wide range of micro-organisms and accumulating evidence shows that it plays an important role in the innate immune defence<sup>3</sup>. When bound to carbohydrate MBL is able to activate the complement system.

30 The complement system may be activated via three different pathways: the classical pathway, the alternative pathway, and the newly described third pathway, the mannan-binding lectin (MBL) pathway which is initiated by the binding of MBL to carbohydrates presented by micro-organisms. The components of the alternative pathway and of the MBL pathway are parts of the innate immune defence, also termed the

35

P 774 DK00

## 2

natural or the non-clonal, immune defence, while the classical pathway involves cooperation with antibodies of the specific immune defence<sup>4</sup>.

5 The human MBL protein is composed of up to 18 identical 32 kDa polypeptide chains<sup>27</sup>, each comprising a short N-terminal segment of 21 amino acids including three cysteine residues, followed by 7 repeats of the collagenous motif Gly-X-Y interrupted by a Gln residues followed by another 12 Gly-X-Y repeats. A small 34 residue 'neck-region' joins the C-terminal  $\text{Ca}^{2+}$ -dependent lectin domain of 93 amino acids with the collagenous part of the molecule<sup>28</sup>.

10

The collagenous regions of the three polypeptide chains combine to form a subunit which is stabilised covalently by disulphide bridges. Individual subunits are joined by disulphide bridges as well as by non-covalently interactions<sup>27</sup>.

15

The concentration of MBL in human serum is largely genetically determined, but reportedly increases up to threefold during acute phase reactions<sup>8</sup>. Three mutations causing structural alterations and two mutations in the promotor region are associated with MBL deficiency<sup>9</sup>.

20

A wide range of oligosaccharides can bind to MBL. As the target sugars are not normally exposed on mammalian cell surfaces at high densities, MBL does not usually recognize self-determinants, but is particularly well suited to interactions with microbial cell surfaces presenting repetitive carbohydrate determinants.

25

Thus, the invention features the use of MBL, purified from natural sources or from material produced by recombinant technologies, or by any other suitable MBL-producing cell line, for the prophylaxis and/or treatment of SARS. The MBL may be given before or after start of the medical treatment and for any duration of time deemed suitable.

30

MBL is believed to exert its anti-SARS activity mainly through its opsonizing activity (preparation of microorganisms for phagocytosis). This activity is dependent on activation of complement after binding of MBL to the microbial surface and deposition of C4b and C3b on the microorganism. MBL can also promote the direct complement-mediated killing of the microorganism through the activation of the terminal lytic

35

P 774 DK00

3

pathway of complement and insertion of the membrane attack complex (MAC) in the membrane. This mechanism is considered of minor importance.

5 It is possible according to the invention to treat SARS prophylactically. By prophylactic treatment with MBL it is possible to prevent subsequent SARS or to reduce the risk of the individual contracting SARS.

10 In another aspect the present invention is related to the use of a composition comprising at least one mannan-binding lectin (MBL) subunit, or at least one oligomer comprising the at least one mannan-binding lectin (MBL) subunit, in the manufacture of a medicament for prophylactic, ameliorating or curative treatment of SARS in an individual initially having low plasma levels of MBL, such as plasma levels of about 0 mg/ml, or plasma levels in excess of 10 ng/. In particular the individual may be genetically disposed to an MBL deficiency or have acquired an MBL deficiency  
15 leading to an increased risk of suffering from infections. Accordingly, the invention also concerns treatment of SARS in individuals suffering from a mannan-binding lectin (MBL) deficiency including any deficiency in the production of MBL and/or function of MBL, in particular however, individuals who have or are suspected to have SARS.

20 In yet another aspect there is provided a method for estimating the probability of the occurrence of any severe outcome of SARS in an individual, said method comprising the step of measuring the concentration of MBL in plasma or serum obtained from the individual, and estimating the probability on the basis of the measured concentration.  
25

Also, by genotyping the individuals in question it is possible to estimate the probability.

### 30 Detailed Description of the Invention

SARS may be prevented and/or treated in individuals independent on their serum MBL level. In particular, SARS may be prevented when administering MBL to these individuals having an MBL level in excess of 10 ng/ml serum. Also, individuals having  
35 an MBL level in excess of 50 ng/ml serum may be in need of treatment, such as

P 774 DK00

4

individuals having an MBL level in excess of 100 ng/ml serum, and individuals having an MBL level in excess of 150 ng/ml serum.

Also the MBL treatment of SARS may be conducted by administering MBL to these individuals in combination with relevant antibiotics, anti-viral agents or anti-fungal agents.

In particular, individuals at risk of acquiring SARS will benefit from being prophylactically treated with MBL.

Generally all individuals exposed to SARS patients should be treated with MBL independent on their specific MBL level. The reason behind this is that SARS may lead to MBL depletion, and therefore an MBL "booster", increasing the MBL level initially will reduce the risk of MBL depletion to a level below a deficiency level, and the immune defence of these patients can be reinforced by administration of recombinant or natural plasma-derived MBL. In particular SARS may be prevented when administering MBL to individuals having an MBL level in excess of 10 ng/ml serum. Also, individuals having an MBL level in excess of 50 ng/ml serum may be in need of treatment, such as individuals having an MBL level in excess of 100 ng/ml serum, and individuals having an MBL level in excess of 150 ng/ml serum.

The present inventors have also shown herein that in particular individuals having an MBL level below 500 ng/ml serum will benefit from the MBL treatment. Consequently, in particular individuals having an MBL level below 400 ng/ml will benefit, such as individuals having an MBL level below 300 ng/ml, such as individuals having an MBL level below 250 ng/ml, such as individuals having an MBL level below 200 ng/ml.

Thus, in a preferred embodiment the present invention relates to the use of MBL for manufacturing of a medicament for treatment of individuals having an MBL level in serum in the range of 10-500 ng/ml, such as in the range of 50-500 ng/ml for treating and/or preventing SARS.

One group of individuals being in need of MBL treatment in order to prevent and/or treat SARS are individuals having a low level of functional MBL, independent on the

P 774 DK00

## 5

level of MBL as such. This is due to the fact that for some mutations of the MBL it has been found that although MBL subunits and oligomers thereof are expressed in serum the functionality thereof are low. The functionality or functional activity of MBL may be estimated by its capacity to form an MBL/MASP complex leading to activation of the complement system. When C4 is cleaved by MBL/MASP an active thio-ester is exposed and C4 becomes covalently attached to nearby nucleophilic groups. A substantial part of the C4b will thus become attached to the coated plastic well and may be detected by anti-C4 antibody.

10 A quantitative TRIFMA for MBL functional activity is constructed by 1) coating microtitre wells with 1 mg mannan in 100 ml buffer; 2) blocking with Tween-20; 3) applying test samples, e.g. diluted MBL preparations 4) applying MBL deficient serum (this leads to the formation of the MBL/MASP complex); alternatively the MBL and the MBL deficient serum may be mixed before application with the microtitre wells; 15 5) applying purified complement factor C4 at 5 mg/ml; 6) incubating for one hour at 37°C; 7) applying Eu-labelled anti-C4 antibody; 8) applying enhancement solution; and 9) reading the Eu by time resolved fluorometry. Between each step the plate is incubated at room temperature and washed, except between step 8 and 9.

20 Estimation by ELISA may be carried out similarly, e.g. by applying biotin-labelled anti-C4 in step 7; 8) apply alkaline phosphatase-labelled avidin; 9) apply substrate; and 10) read the colour intensity.

25 The functionality may be expressed as the specific activity of MBL, such as 1 unit of MBL activity per ng MBL. A non-functional MBL may be defined as MBL having a specific activity less than 50 % of plasma MBL specific activity, such as less than 25 % of plasma MBL specific activity, wherein the plasma MBL is purified from an individual not suffering from any MBL mutations. In particular the reference plasma MBL is plasma pool LJ 6.57 28/04/97.

30 Thus, the present invention also relates to the prevention and/or treatment of SARS in individuals having a mutation in their MBL gene leading to a reduced expression of MBL and/or expression of non-functional MBL.

P 774 DK00

6

In particular such mutations in the MBL gene can lead to a change of aminoacid number 52 (numbering including the leader peptide of MBL) from arginine to cysteine, aminoacid number 54 from glycine to aspartic acid or amino acid number 75 from glycine to glutamic acid.

5

Also mutations in the promoter region of the MBL gene can lead to lowered levels of MBL. In particular mutations at position -221 have an influence on the expression of MBL.

10 The MBL sequence may be found in swiss.prot under accession No: 11226

The MBL composition used to manufacture an MBL medicament may be produced from any MBL source available. The MBL source may be natural MBL, whereby the MBLs are produced in a native host organism, meaning that MBL is produced by a cell normally expressing MBL. One usual method of producing an MBL composition is by extraction of MBL from human body liquids, such as serum or plasma, but MBL may also be harvested from cultures of hepatocytes.

15

In another aspect the MBL oligomers are produced by a host organism not natively expressing an MBL polypeptide, such as by recombinant technology.

20

In a first embodiment the MBL source may be serum, from which an MBL composition is obtained by purification from serum, plasma, milk product, colostrum or the like by a suitable purification method, such as affinity chromatography using carbohydrate-derivatised matrices, such as mannose or mannan coupled matrices. Such a method is discussed in WO99/64453, wherein the purification process is followed by a virus-removal step in order to remove infectious agents from the MBL source, since one of the major problems with proteins purified from body liquids is the risk of introducing infectious agents in combination with the desired protein. WO99/64453 is hereby incorporated by reference.

25

30

The MBL composition used to manufacture an MBL medicament preferably comprises MBL oligomers having a size distribution substantially identical to the size distribution of MBL in serum, such as a size distribution profile at least 50 % identical to the size distribution profile of MBL in serum. By identical is meant that at least

35

P 774 DK00

7

50 % of the oligomers has an apparent molecular weight higher than 200 kDa, when analysed by SDS-PAGE and/or Western blot.

5 In a more preferred embodiment the size distribution profile is at least 75 % identical to the size distribution profile of MBL in serum, such as at least 90 % identical to the size distribution profile of MBL in serum, and more preferred at least 95 % identical to the size distribution profile of MBL in serum.

10 When purifying from an MBL source initially having another size distribution profile it is preferred that the affinity chromatography used to purify from the MBL source favours purification of oligomers having an apparent molecular weight higher than 200 kDa. This is obtained by using a carbohydrate-derivatized matrix having substantially no affinity to subunits and/or dimers of MBL. Preferably the carbohydrate-derivatized matrix has affinity for substantially only tetrameric, pentameric and/or  
15 hexameric recombinant MBLs.

The matrix may be derivatized with any carbohydrate or carbohydrate mixture whereto MBL binds and for which binding of the higher oligomers of MBL are favoured. The carbohydrate-derivatized matrix is preferably a hexose-derivatized matrix, such as a mannose- or a N-acetyl-glucosamin derivatized matrix, such as most  
20 preferably a mannose-derivatized matrix.

The selectivity of the carbohydrate-derivatized matrix is obtained by securing that the matrix as such, i.e the un-derivatized matrix has substantially no affinity to MBL polypeptides, in particular no affinity to MBL trimers or smaller oligomers. This may  
25 be ensured when the matrix as such is carbohydrate-free. In particular the matrix should not contain any Sepharose or the like. It is preferred that the matrix consists of a non-carbohydrate containing polymer material, such as Fractogel®TSK beads

30 The matrix may be in any form suitable for the chromatography, mostly in the form of beads, such as plastic beads.

After application of the MBL source the column is washed, preferably by using non-denaturing buffers, having a composition, pH and ionic strength resulting in elimination of proteins, without eluting the higher oligomers of MBL. Such as buffer may be  
35



P 774 DK00

8

TBS. Elution of MBL is performed with a selective desorbing agent, capable of efficient elution of highed oligomers of MBL, such as TBS comprising a desorbing agent, such as EDTA (for example 5 mM EDTA) or mannose (for example 50 mM mannose), and MBL oligomers are collected. Such a purification method is described in co-pending International patent application No. WO 00/70043.

In a preferred aspect a clinical grade MBL composition is obtained by using an MBL source produced by recombinant technology, wherein the MBL source is the culture media from culturing of MBL producing cells.

Thus, the present invention encompasses MBL produced by a process of producing a recombinant mannan binding lectin (MBL), comprising the steps of:

- preparing a gene expression construct comprising a DNA sequence encoding a MBL polypeptide or a functional equivalent thereof,
- transforming a host cell culture with the construct,
- cultivating the host cell culture, thereby obtaining expression and secretion of the polypeptide into the culture medium, followed by
- obtaining a culture medium comprising human recombinant MBLs.

The culture medium comprising the human recombinant MBL polypeptides may then be processed as described above for purification of MBL.

The MBL polypeptide is preferably a mammalian MBL polypeptide, such as more preferably a human MBL polypeptide. The gene expression construct may be produced by conventional methods known to the skilled person, such as described in US patent No. 5,270,199.

In another embodiment the gene expression construct is prepared as described in WO 00/70043.

P 774 DK00

9

The expression is preferably carried out in e.g. mammalian cells, the preparation according to the invention results from the use of an expression vector comprising intron sequence(s) from an MBL gene and at least one exon sequence. Regarding the transgenic animals as expression system this term is in this context animals  
5 which have been genetically modified to contain and express the human MBL gene or fragments or mimics hereof.

In addition to the purification method it is preferred that the gene expression construct and the host cell also favours production of higher oligomers, which has been  
10 found to be possible by using a gene expression construct comprising at least one intron sequence from the human MBL gene or a functional equivalent thereof.  
malian cells and cells from insects.

Consequently, the MBL composition may be used for preventing and/or treating  
15 SARS in an individual wherein the microbial species is a fungus, a yeast, a protozoa, a parasite and/or a bacteria.

The medicament may be produced by using the eluant obtained from the affinity chromatography as such. It is however preferred that the eluant is subjected to further  
20 purification steps before being used.

In addition to the MBL oligomers, the medicament may comprise a pharmaceutically acceptable carrier substance and/or vehicles. In particular, a stabilising agent may be added to stabilise the MBL proteins. The stabilising agent may be a sugar alcohol, saccharides, proteins and/or amino acids. Examples of stabilising agents may  
25 be maltose or albumin.

Other conventional additives may be added to the medicament depending on administration form for example. In one embodiment the medicament is in a form suitable for injections. Conventional carrier substances, such as isotonic saline, may be  
30 used.

In another embodiment the medicament is in a form suitable for pulmonary administration, such as in the form of a powder for inhalation or creme or fluid for topical  
35 application.

P 774 DK00

10

The route of administration may be any suitable route, such as intravenously, intramuscularly, subcutaneously or intradermally. Also, pulmonal or topical administration is envisaged by the present invention.

5

Normally from 1-100 mg is administered per dosage, such as from 2-10 mg, mostly from 5-10 mg per dosage depending on the individual to be treated, for example about 0.1 mg/kg body weight is administered.

10

The use of an MBL composition for the manufacture of a medicament may also further comprise the manufacture of another medicament, such as an anti-fungal, anti-yeast, anti-bacterial and/or anti-viral medicament for obtaining a kit-of-parts.

15

The anti-viral medicament may be a medicament capable of virus attenuation and/or elimination.

20

The invention also relates to an aspect of using a measurement of the MBL level as a prognostic marker for the risk of the individual of acquiring SARS and thereby an indicative of the need for treatment. In particular an MBL level below 500 ng/ml is a prognostic marker indicative for treatment with MBL.

25

Thus, the present invention also relates to a method of using an MBL composition for preventing and/or treating SARS in an individual, the method comprising the steps of:

- i) determining serum levels of MBL in an individual,
- ii) estimating the probability of the occurrence of a significant clinical SARS in the individual, and optionally,

30

administering an MBL composition to the individual.

35

The MBL level is measured in serum or plasma, and may be determined by time resolved immunofluorescent assay (TRIFMA), ELISA, RIA or nephelometry.

P 774 DK00

11

Also the MBL levels may be inferred from analysis of genotypes of the MBL genes as discussed above in relation to mutations of MBL leading to a decreased MBL level.

## 5 Example

### MBL serum levels in patients suffering from SARS

10 Patients are selected among individuals presenting clinically significant SARS as defined above. Patients are identified by retrospective computer search of the patient database.

15 Before entering treatment blood is drawn into evacuated glass tubes containing EDTA (final concentration about 10 mM). The plasma is aliquoted and kept at  $-80^{\circ}\text{C}$  until assay. Plasma samples are similarly obtained from healthy blood donors. The patients are free of infections at the time of blood sampling.

20 The concentration of MBL is determined by a time resolved immunofluorescent assay (TRIFMA). Microtitre wells (fluoroNunc, Nunc, Kamstrup, Denmark) are coated with antibody by incubation overnight at room temperature with 500 ng anti-human MBL antibody (Mab 131-1, Statens Serum Institut, Copenhagen, Denmark) in 100  $\mu\text{l}$  PBS (0.14 M NaCl, 10 mM phosphate, pH 7.4). After wash with Tween-containing buffer (TBS, 0.14 M NaCl, 10 mM Tris/HCl, 7.5 mM  $\text{NaN}_3$ , pH 7.4 with 0.05% Tween 20) test samples (plasma 1/20) and calibrator dilutions are added in TBS/Tween with  
25 extra NaCl to 0.5 M and 10 mM EDTA.

30 After overnight incubation at  $4^{\circ}\text{C}$  and wash, the developing europium-labelled antibody (12.5 ng Mab 131-1 labelled with the Eu-containing chelate, isothiocyanato-benzoyl-diethylene-triamine-tetra acetic acid, according to the manufacturer, Wallac, Turku, Finland) is added in TBS/Tween with 25  $\mu\text{M}$  EDTA.

35 Following incubation for 2 h and wash, fluorescence enhancement solution is added (Wallac) and the plates are read on a time resolved fluorometre (Delfia 1232, Wallac). The calibration curve is made using dilutions of one plasma, which is kept aliquoted at  $-80^{\circ}\text{C}$ .

P 774 DK00

12

Based on the above outlined method, the MBL serum level of patients with SARS as compared to non-SARS patients is compared.

5

10

P 774 DK00

13

## References

1. Weis WI, Taylor ME and Drickamer K (1998) The C-type lectin superfamily in the immune system. *Immunological Reviews* 163: 19-34
- 5 2. Holmskov, U., Malhotra, R., Sim, R.B., and Jensenius, J.C. (1994) Collectins: collagenous C-type lectins of the innate immune defense system. *Immunol.Today* 15:67-74.
3. Turner, M.W. (1996) Mannose-binding lectin: the pluripotent molecule of the innate immune system. *Immunol.Today* 17:532-540.
- 10 4 Janeway CA, Travers P, Walport M and Capra JD (1999) Immunobiology, the immune system in health and disease, Fourth Edition, Churchill Livingstone)
5. Matsushita, M. and Fujita, T (1992). Activation of the classical complement pathway by mannose-binding protein in association with a novel C1s-like serine protease. *J.Exp.Med.* 176:1497-1502.
- 15 6. Thiel S, Vorup-Jensen T, Stover CM, Schwaebble W, Laursen SB, Poulsen K, Willis AC, Eggleton P, Hansen S, Holmskov U, Reid KB and Jensenius JC (1997) A second serine protease associated with mannan-binding lectin that activates complement. *Nature*, 386(6624): 506-510
7. Stover CM, Thiel S, Thelen M, Lynch NJ, Vorup-Jensen T, Jensenius JC and Schwaebble WJ (1999) Two constituents of the initiation complex of the mannan-binding lectin activation pathway of complement are encoded by a single structure gene. *J Immunol* 162: 3481-3490
- 20 8. Thiel S, Holmskov U, Hviid L, Laursen SB and Jensenius JC (1992) The concentration of the C-type lectin, mannan-binding protein, in human plasma increases during an acute phase response. *Clin Exp Immunol* 90: 31-35
- 25 9. Madsen, H.O., Garred, P., Kurtzhals, J.A., Lamm, L.U., Ryder, L.P., Thiel, S., and Svejgaard, A. (1994) A new frequent allele is the missing link in the structural polymorphism of the human mannan-binding protein. *Immunogenetics* 40:37-44.
10. Summerfield JA, Ryder S, Sumiya M, Thursz M, Gorchein A, Montell MA and Turner MW (1995) Mannose binding protein gene mutations associated with unusual and severe infections in adults. *Lancet* 345: 886-889
- 30 11. Garred P, Madsen HO, Hofmann B and Svejgaard A (1995) Increased frequency of homozygosity of abnormal mannan binding protein alleles in patients with suspected immunodeficiency. *Lancet* 346: 941-943

P 774 DK00

14

12. Summerfield JA, Sumiya M, Levin M and Turner MW (1997) Association of mutations in mannose-binding protein gene with childhood infection in consecutive hospital series. *BioMed J* 314: 1229-1232
13. van Emmerik, LC, Kuijper, EJ, Fijen, CAP, Dankert, J, and Thiel, S (1994) Binding of mannan-binding protein to various bacterial pathogens of meningitis. *Clin.Exp.Immunol.* 97:411-416.
14. Jack DL, Dodds AW, Anwar N, Ison CA, Law A, Frosch M, Turner MW and Klein NJ (1998) Activation of complement by Mannose-binding lectin on isogenic mutants of *Neisseria meningitidis* serogroup B. *J Immunol* 160: 1346-1353
15. Miller, M.E., Seals, J., Kaye, R., and Levitsky, L.C. (1968) A familial, plasma-associated defect of phagocytosis. A new case of recurrent bacterial infections. *The.Lancet* :60-63.
16. Super, M., Thiel, S., Lu, J., Levinsky, R.J., and Turner, M.W. (1989) Association of low levels of mannann-binding protein with a common defect of opsonisation. *Lancet* 2:1236-1239.
17. Nielsen, S.L., Andersen, P.L., Koch, C., Jensenius, J.C., and Thiel, S. (1995) The level of the serum opsonin, mannann-binding protein in HIV-1 antibody-positive patients. *Clin. Exp. Immunol.* 100:219-222.
18. Christiansen, O.B., Kilpatrick, D.C., Souter, V., Varming, K., Thiel, S., Jensenius, J.C. (1999) Mannann-binding lectin deficiency is associated with unexplained recurrent miscarriage. *Scand. J. Immunol.*, 49, 193-196
19. Garred, P, Harboe, M, Oettinger, T, Koch, C, and Svejgaard, A (1994) Dual role of mannannbinding protein in infections: Another case of heterosis ? *Eur.J.Immunogen.* 21:125-131.
20. Hoal-Van Helden EG, Epstein J, Victor TC, Hon D, Lewis LA, Beyers N, Zurakowski D, Ezekowitz AB, Van Helden PD (1999) Mannose-binding protein B allele confers protection against tuberculous meningitis. *Pediatr Res* 45:459-64
21. Fischer, PB, Ellerman-Eriksen, S, Thiel, S, Jensenius, JC, and Mogensen, SC (1994) Mannann-binding protein and conglutinin mediate enhancement of herpes simplex virus type-2 infection in mice. *Scand J Immunol* 39:439-445.
22. Valdimarsson H, Stefansson M, Vikingsdottir T, Arason GJ, Koch C, Thiel S and Jensenius JC (1998) Reconstitution of opsonizing activity by infusion of mannann-binding lectin (MBL) to
24. Pizzo, PA (1993), Management of fever in patients with cancer and treatment-induced neutropenia, *N Eng J Med*, 328, 1323-1332.

P 774 DK00

15

25. Aittoniemi, J., Miettinen, A., Laine, S., Sinisalo, M., Laippala, P., Vilpo, L., Vilpo, J. (1999), Opsonising immunoglobulins and mannan-binding lectin in chronic lymphocytic leukemia, *Leuk Lymphoma* Jul;34(34):3815
- 5 26. Lehnbecher T, Venzon D, de Haas M, Chanock SJ, Kuhl J. (1999) Assessment of measuring circulating levels of interleukin6, Interleukin8, Creactive protein, soluble Fc gamma receptor type III, and mannosebinding protein in febrile children with cancer and neutropenia. *Clin Infect Dis*, Aug;29(2):4149.
- 10 27. Lu, J., Thiel, S., Wiedemann, H., Timpl, R. & K.B.M. Reid (1990) Binding of the pentamer/hexamer forms of mannan-binding protein to zymosan activates the pro-enzyme C1r2C1s2 complex, of the classical pathway of complement without involvement of C1q. *J. Immunol.* 144:2287-2294.
28. Sastry, K., Herman, G.A., Day, L., Deignan, E., Bruns, G., Morton, C.C. & R.A.B. Ezekowitz (1989) The human mannose-binding protein gene. *J. Exp. Med.* 170:1175-1189.
- 15 29. Lipscombe, R.J., Sumiya, M., Summerfield, J.A. & M.W. Turner (1995) Distinct physicochemical characteristics of human mannose-binding protein expressed by individuals of differing genotype. *Immunology* 85:660-667.



P 774 DK00

16

**Claims**

1. Use of a composition comprising at least one mannan-binding lectin (MBL) subunit, or at least one mannan-binding lectin (MBL) oligomer comprising the at least one mannan-binding lectin (MBL) subunit, in the manufacture of a medicament for prophylaxis and/or treatment of Severe Acute Respiratory Syndrome.  
5
2. The use of claim 1, wherein the composition comprises at least one mannan-binding lectin (MBL) oligomer comprising the at least one mannan-binding lectin (MBL) subunit.  
10
3. The use of claim 2, wherein said oligomer is preferably selected from the group of oligomers consisting of tetramers, pentamers and/or hexamers.
- 15 4. The use of claim 1, wherein the individual has a serum level of MBL in excess of 10 ng/ml serum.
5. The use of claim 1, wherein the individual has a serum level of MBL in excess of 50 ng/ml serum.  
20
6. The use of any of claims 4 or 5, wherein the serum MBL level is the functional serum MBL level.
- 25 7. The use of claim 1, further comprising the manufacture of an antimicrobial medicament capable of attenuation and/or elimination a microbial species for obtaining a kit-of-parts.
8. The use of claim 7, further comprising the manufacture of an antibacterial medicament capable of bacterial attenuation and/or elimination for obtaining a kit-of-parts.  
30
9. The use of claim 1, wherein the MBL subunit or the MBL oligomer is produced in a native host organism.

P 774 DK00

17

10. The use of claim 9, wherein the native host organism is a human cell natively expressing the MBL subunit or the MBL oligomer.
- 5 11. The use of claim 1, wherein the MBL subunit or MBL oligomer is produced by a host organism not natively expressing an MBL polypeptide.
12. The use of claim 1, wherein the MBL subunit or the MBL oligomer is produced by a method comprising at least one step of recombinant DNA technology in vitro.
- 10 13. The use of claim 11 or 12, wherein the production of the MBL subunit or the MBL oligomer is controlled by an expression control sequence not natively associated with MBL polypeptide expression.
- 15 14. The use of any of claims 9 to 13, wherein the MBL subunit or the MBL oligomer is isolated from the host organism.
15. The use of claim 14, wherein the MBL subunit or the MBL oligomer is isolated by a method comprising at least one step involving affinity chromatography.
- 20 16. The use of claim 13, wherein the affinity chromatography step is capable of isolating MBL tetramers, pentamers and/or hexamers from a composition further comprising additional MBL oligomers and/or MBL subunits.
- 25 17. The use of any of claims 11 to 16, wherein the MBL subunit and/or the MBL oligomer is free from any impurities naturally associated with the MBL when produced in a native host organism.
- 30 18. The use of claim 1, wherein the MBL subunit is a mammalian MBL subunit.
19. The use of claim 18, wherein the mammalian MBL subunit is a human MBL subunit.
- 35 20. The use of claim 1, wherein the medicament is administered to the individual prior to another treatment.

P 774 DK00

18

21. The use of any of the preceding claims, wherein the treatment is a prophylactic treatment.
5. 22. The use of any of claims 1 to 21, wherein the medicament is a booster of MBL serum levels in an individual having MBL serum levels above a predetermined minimum MBL serum level of 10 ng/ml.
10. 23. The use of claim 22, wherein the individual has MBL serum levels below a predetermined maximum MBL serum level of 500 ng/ml.
24. The use of claim 1 or 23, wherein the individual has serum levels of MBL in excess of 75 ng/ml.
15. 25. The use of claim 1 or 23, wherein the individual has serum levels of MBL in excess of 100 ng/ml.
26. The use of claim 1 or 23, wherein the individual has serum levels of MBL in excess of 150 ng/ml.
20. 27. The use of claim 1 or 24, wherein the individual has serum levels of MBL below 500 ng/ml.
28. The use of claim 1 or 24, wherein the individual has serum levels of MBL below 400 ng/ml.
25. 29. The use of claim 1 or 24, wherein the individual has serum levels of MBL below 300 ng/ml.
30. 30. The use of any of the preceding claims, wherein serum or plasma levels of MBL in the individual are determined by quantitative analysis.
35. 31. The use of claim 30, wherein the analysis comprises at least one of ELISA, TRIFMA, RIA or nephelometry.

P 774 DK00

19

32. A method of using an MBL composition for preventing and/or reducing SARS in an individual, the method comprising the steps of:

5

- a) determining serum levels of MBL in an individual,
- b) estimating the probability of the occurrence of a significant clinical SARS in the individual, and optionally,
- c) administering an MBL composition to the individual.